Abstract Osteochondral injuries are common in humans and are relatively difficult to manage with current treatment options. The combination of novel biomaterials and expanded progenitor or stem cells provides a source of therapeutic and immunologically compatible medicines that can be used in regenerative medicine. However, such new medicinal products need to be tested in translational animal models using the intended route of administration in humans and the intended delivery device. In this study, we evaluated the feasibility of an arthroscopic approach for the implantation of biocompatible copolymeric poly-D,Llactide-co-glycolide (PLGA) scaffolds in an ovine preclinical model of knee osteochondral defects.
Introduction
Articular cartilage focal defects represent a common condition affecting the knee and play a significant role in the subsequent development of degenerative joint disease. The response to injury depends on the severity and depth of the lesion, but in general the healing potential is very limited. In this scenario, chondral lesions involving the subchondral bone usually result in fibrocartilage scar tissue refilling, which has poorer biomechanical and biochemical features compared to hyaline cartilage (Alford and Cole 2005) .
Since the simultaneous regeneration of both cartilage and subchondral bone can be approached by the use of porous biopolymeric scaffolds that can contribute to (1) preserve the structure of the lesion area and (2) absorb bone marrow from the focal osteochondral injury, permitting bone remodelling and differentiation of neighbouring stem cells, we evaluated its use in a preclinical model of osteochondral injury. In particular, a large animal model was chosen in order to evaluate the viability of an arthroscopic approach for the implantation of a copolymeric poly-D,L-lactide-co-glycolide (PLGA) scaffold using standard instrumentation and techniques in human clinical practice. This is an important point, since there is a great deal of interest in the possibility of using arthroscopy in preclinical animal models for the development of new techniques and investigate the performance of novel implants in situ using minimally invasive approaches (Allen et al. 1998 ).
An osteochondral defect was created in the medial femoral condyle of the ovine stifle joint, since sheep is a representative animal model for studying a range of orthopaedic conditions and treatments because of its similar size and anatomy to the human knee. Although no animal model is completely ideal, sheep is a reasonable experimental animal for surrogate orthopaedic research directed at efficacy, safety, and mechanism of action (Simon and Aberman 2010) and, in fact, it has been previously used in several other studies for the treatment of chondral and osteochondral lesions (as reviewed in Ahern et al. 2009 ).
Materials and methods

Animals
The surgical procedures were developed in five cadavers that were euthanized for reasons unrelated to the current study. For the in vivo study, six healthy 2-year old ewes of the Ripollesa-Lacona breed were obtained from Servei de Granges i Camps Experimentals (SGCE, Bellaterra, Spain). During the preand post-operative procedures, animals were housed together, fed a standard diet and allowed access to water ad libitum. All animal care and experimental procedures were approved by the Universitat Autòno-ma de Barcelona's Ethical Committee on Human and Animal Experimentation (Ref. No. CEAAH 501) , and registered by the Departament de Medi Ambient de la Generalitat de Catalunya (Reg. No. 3666).
Study design
Two surgical procedures were performed in each animal. The first procedure involved an arthrotomy to harvest a cartilage biopsy for subsequent chondrocyte isolation and expansion (Suppl. Fig. 1A and 1B). The second procedure was performed after 4 weeks, and involved creation of a standardized osteochondral defect bilaterally in the medial femorotibial condyles via an arthroscopic approach (Suppl. Fig. 1D and 1F) . Each of the osteochondral lesions produced in the 12 knees were included in one of any of the three treatments detailed next and described in Table 1 : (a) 4 knees received scaffold seeded with expanded Isolation, culture and scaffold-seeding of articular chondrocytes
The right shoulder joint was aseptically prepared and exposed with a craniolateral approach to the shoulder (Suppl. Fig. 1A ). An approximately 3 cm-long incision was made in the skin and subcutaneous tissue, extending from the acromion process to the proximal humerus. The acromial portion of the deltoideus muscle was retracted caudally, and a lateral incision of the articular capsule was made between the glenoid rim and the humeral head. The humerus was rotated internally and an articular cartilage layer of 1 mm thick and 6 mm long was harvested from the head of humerus, using a curette. Cartilage was pierced and used as a source of chondrocytes (Suppl. Fig. 1 ). To do this, cartilage was washed and soaked with phosphatebuffered saline solution (PBS, HyClone, Logan, UT, USA) and immediately processed in the laboratory. The fragments of cartilage were minced, washed three times in PBS, and digested with 0.2 % (w/v) Collagenase B (Roche) for 24 h. Cells and tissue were resuspended in 10 mL of DMEM (Dulbecco's modified Eagle's medium, GIBCO-BRL/Life Technology, Carlsbad, CA, USA) supplemented with 10 % (v/v) foetal calf serum (FCS, Biological Industries, Kibbutz Beit Haemek, Israel) and centrifuged at 400 g for 5 min. Cells were washed in PBS and cultured in a T-25 flask in DMEM medium containing 10 % (v/v) FCS, in a humidified 5 % CO 2 incubator. After cell attachment and mesenchymal-morphology conversion, cells were scaled-up by seeding T-150 flasks at 2,500 cell/cm 2 . Cell number and viability were determined by the haemocytometer-based trypan blue dye exclusion assay.
The cells were cultured in low glucose DMEM medium supplemented with Streptomycin (0.167 g/L, Sigma-Aldrich, St. Louis, MO, USA), Kanamycin (0.075 g/L, Sigma-Aldrich) and 10 % foetal calf serum (FCS, Biological Industries). Cells were passaged until passage 4 under a humidified atmosphere of 5 % carbon dioxide at 37°C, using 0.25 % trypsin (GIBCO-BRL) and counted with a haemocytometer. The cultured chondrocytes obtained from each sheep were reseeded onto three-dimensional PLGA scaffolds in a minibioreactor (Hexascreen Culture Technologies S.L., Cerdanyola del Vallès, Spain) (Suppl. Fig. 1 ). Briefly, 3 9 10 6 cells were inoculated in each minibioreactor, where a PLGA scaffold was fixed using a 25G needle, and stirred at 200 rpm for 24 h incubation time in a total final volume of 12 mL. The amount of inoculum was determined in pilot experiments indicating the maximum load of cells absorbed by the scaffold (data not shown).
Scanning electron microscopy
Samples were fixed in 2.5 % glutaraldehyde and 2 % paraformaldehyde in PBS (pH 7) and dehydrated in ethanol series (15 min in each 30-50-70-90-100-100 %) to absolute ethanol and immediately transferred to acetone before being critical-point dried and gold-coated using a Sputter Coater (K550, Coating Attachment, Emitech, Ashford, U.K.). Samples were examined with an HITACHI S-570 electron microscope (Tokyo, Japan) at a voltage of 15 kV.
Scaffolds
PLGA scaffolds were manufactured in-house following a solution-casting/salt-leaching technique using PLGA particles with an inherent viscosity of 0.55-0.75 dL/g (Lactel) as described elsewhere (Mikos et al. 1994) . Briefly, polymeric PLGA particles were first dissolved in chloroform. Then, sieved salt particles ranging 300-500 lm were dispersed in the polymer solution at a 9:1 ratio (NaCl:PLGA). The mixture was casted into a mould with a cylindrical shape, with a diameter of 4 mm and with 7 mm high. After the evaporation of the solvent, the salt particles were extracted by washing the polymer with distilled water for 48 h. Then the scaffolds were dried first at air temperature for 24 h and then vacuum dried for 24 h. Finally, the scaffolds were gamma sterilized (20 kGy) and stored at -20°C.
Osteochondral defect creation and arthroscopic implantation
The creation of osteochondral defects and the introduction of the test items were performed arthroscopically (Suppl. Fig. 1 ). Each joint was approached via a stab incision lateral to the distal aspect of the patellar ligament, allowing the insertion of the arthroscope with camera for the visualization of the medial condyle. A mechanical shaver was used to remove the fat pad allowing a clearer view. For this purpose, a second stab incision was made medial to the distal aspect of the patellar ligament to allow the shaver insertion. Once cleaned, the shaver was removed. A mosaicplasty instrument set (Smith and Nephew Inc, Memphis, TN, USA), consisting of a donor and a receptor cannulae, was used to create the lesion and to place the scaffold (Suppl. Fig. 1D ). For this purpose, the cylindrical hollow punch with an inner diameter of 2.7 mm (donor cannula) was placed through the second stab incision, previously used. This instrument was used to perform a cylindrical osteochondral lesion of diameter 3.5 and 5 mm depth in the caudal aspect of the medial femoral condyle of each knee. The scaffold of cylindrical shape and 4 mm diameter and 7 mm high was placed through the receptor canula, filling the lesion by the application of moderate force to the syringe piston (Suppl. Fig. 1F ). The joints were irrigated by saline solution (NaCl-0.9, BBraun Medical SA) at room temperature during surgery.
Magnetic resonance imaging MRI examination was performed on both knees of each animal under general anaesthesia, using a 0.2 T unit with open permanent magnet (Vet-MR, Esaote S.p.a., Genova, Italy). First group of animals was examined at 11 weeks post-treatment and the second group, at 19 weeks post-treatment.
Animals were positioned in sternal recumbency with the leg extended and symmetrically placed inside a dual phased array coil.
Sequences included axial, coronal and sagittal: sagittal high resolution spin echo T1 (TR/TE 590/26, DFOV 20 cm, slice thickness 4 mm) and high resolution spin echo T1 coronal (TR/TE 690/26, DFOV 22 cm, slice thickness 3 mm); sagittal sequences in Gradient echo (TR/TE 600/22, FA = 408, DFOV 22 cm, slice thickness 4 mm); sagittal STIR imaging (TR/TE/TI 1560/24/75, DFOV 23 cm, slice thickness 4 mm) and coronal STIR imaging (Short T1 Inversion Recovery) for fat suppression (TR/TE/TI 1840/24/75, DFOV 23 cm, slice thickness 3 mm); axial PD/T2 Turbo Multiecho imaging (TR/TE 2800/28 and 2800/90, DFOV 22, slice thickness 4 mm).
Macroscopic assessment
The animals from the two experimental groups were sedated with an IM injection of 0.02 mg/kg of midazolam and euthanised by IV injection of 12 mg/kg pentobarbital (Dolethal 20 mg/100 mL, Vetoquinol S.A., Paris, France).
Both stifle joints were harvested, grossly evaluated blindly by CF, JB and FG, and photographed. The gross appearance of repaired tissues was assessed in accordance with the International Cartilage Repair Society (ICRS) classification (van den Borne et al. 2007 ). Biologically acceptable regeneration was defined as having smooth, firm repair tissue that filled the defect and appeared attached to the adjacent cartilage. Samples were excised in blocks including all the implanted tissue and the surrounding native tissue, and were fixed in a 4 % PFA (paraformaldehyde, Sigma-Aldrich) solution, for histological analysis.
Histological evaluation and immunohistochemical procedures
Condyles were fixed in 4 % PFA solution at room temperature for 2 weeks, decalcified with 5 % formic acid for 4-6 weeks and embedded in paraffin for subsequent histological and immunohistochemical procedures. Microtome sections 4 lm thick were cut in sagittal plane sections and stained with haematoxylin/eosin (H&E, Sigma-Aldrich) and Safranin O (Sigma-Aldrich). The success of the treatment was evaluated blindly by PJF following the Histological scoring Grading Scale on at least 4 sequential histological sections (Mainil-Varlet et al. 2001) .
The presence of Collagen type II and Sox9 was detected by immunohistochemical techniques using polyclonal antibodies (MAB 8887, Chemicon (EMD Millipore Corporation, Billerica, MA, USA); and AB5535, Chemicon, respectively). Briefly, paraffin sections were deparaffinized and hydrated. For collagen type II, sections were also treated with 0.1 % Pepsin (SigmaAldrich) in HCl 0.01N for 20 min. For both collagen type II and sox9, endogenous peroxidase activity was blocked with hydrogen peroxide for 30 min and washed in 3 % bovine serum albumin (BSA, Sigma-Aldrich) in Phosphate Buffered Saline (PBS, Sigma-Aldrich). The sections were then incubated with either the antibody against collagen type II (dilution 1:200) or sox9 (dilution 1:200) overnight at 4°C. Antibody binding was visualized by using Universal LSAB TM 2 Kits (Dako, Glostrup, Denmark) in combination with diaminobenzidine (DAB) according to the manufacturer's instructions. The sections were counterstained with haematoxylin. 
Statistical analysis
To verify the comparability of the treatment groups, comparisons with regard to macroscopic evaluation and histological grade were performed using a non-parametric Kruskal-Wallis statistical analysis (n = 4) with the GraphPad Prism program (GraphPad software).
Results
Production of scaffolds and cell/scaffold constructs
Scanning electron microscopy was used to assess the microstructure of the porous PLGA scaffolds produced. They displayed high interconnectivity of pores, and a 3D structure that facilitated migration of cells within the scaffold (Fig. 1a, b) . Autologous chondrocytes were expanded in vitro yielding a therapeutic dose of 3 9 10 6 cells/ scaffold (Fig. 1c) . Each PLGA scaffold and its corresponding dose of chondrocytes were incubated together in a single-use bioreactor resulting in colonization rates of more than 70 %: that is a number of cells seeded ranging between 2.2 9 10 6 and 2.4 9 10 6 cells/scaffold, as determined by indirect counting of non-seeded cells present on the supernatant. Histological analysis of seeded scaffolds showed cells consistently distributed within the PLGA structure and tightly attached to the surface (Fig. 1d) . MRI evaluation at 11 and 19 weeks (prior to euthanasia at 12 and 20-week post-surgery, respectively) revealed osteochondral sclerotic lesions in all untreated knees (Fig. 2a, d) . Most of the defects treated with scaffold constructs, either with or without cells, presented continuity of the surface, which was not observed in the untreated group (Fig. 2) .
Macroscopic assessment and histological results
Animals were euthanized at 12 and 20 weeks posttreatment, and the repair process was evaluated macroscopically. No evidence of infection or fibrinous overgrowth on the joint surface was observed. Taken together, both scores from groups euthanized at 12 and 20 weeks, knees treated with cell-seeded scaffolds presented the best macroscopic results and showed differences that were statistically significant (p \ 0.01) compared to untreated controls (CS = 9.0 ± 2.1; S = 8.8 ± 0.5; L = 4.3 ± 1.0; Fig. 3g) .
At the histological level, a repetitive pattern was observed on the surface of the perilesional zone in all samples, consisting in a marked decrease in cellular density, low intensity of Safranin O staining and presence of clusters of chondrocytes, preferentially in the most superficial layers and the more numerous, the closer to the area of the lesion (Fig. 4) .
Although macroscopically fibrous tissue was only observed in specimens from the 20-week time point, all 12 and 20-week untreated knees displayed at the histological level some amount of fibrous repair tissue of low quality lacking continuity of the cartilage surface surrounding the damaged area.
Collagen II positive immunostaining displayed a uniform sheet pattern distribution on the superficial cartilage in those lesions that were treated with cell- Fig. 3 Macroscopic aspect of knees. The top images were taken at 12 weeks post arthroscopy: a knee displaying a condyle (sample F12left) suffering arthritis as a consequence of the untreated osteochondral lesion; b lesion treated with cell-free PLGA scaffold and showing a good integration of the implant (sample F6left) and merely displaying a slight erosion on the surface; and c defect treated with cell-seeded PLGA scaffold (sample F6right), where the arrow marks the integration site of the repair tissue next to the border zone of the native tissue, which appears almost identical. Bottom images show macroscopic findings at 20 weeks post arthroscopy: d untreated lesion in sample F17left, where the arrow marks the defect site; e lesion treated with cell-free PLGA scaffold in sample F30right, where a repair tissue (arrow) appears below the level of the native articular cartilage; and f cell-seeded PLGA scaffold treatment in sample F17r, offering repair tissue well integrated (arrows), and levelled with the surrounding native articular cartilage. g Graphical representation of the scores obtained at 12 and 20 weeks grouped together according to each treatment, where the average from each group is also graphically represented to highlight the similarity in their values. A significant statistical difference (p \ 0.01) was observed between the group treated with cell-seeded scaffold compared to the untreated lesion. CS cell-seeded scaffold, S scaffold, L untreated lesion free scaffolds (at 20 weeks post-treatment; Fig. 4k ) and cell-seeded scaffolds (both at 12 and 20-week post-treatment; Fig. 4i, l) . Expression of Sox9 was observed in cells present within the hyaline cartilage (Fig. 4n) . In all samples, Sox9 signal was found in most superficial cells of native hyaline cartilage and in clusters of chondrocytes located superficially in the perilesional area.
Taken together the scores from the histology and immunohistochemistry for each treatment, no statistically significant differences (p [ 0.01) were found among any of the experimental groups (CS = 19.0 ± 7.1; S = 22.0 ± 5.0; L = 10.5 ± 9.0; Fig. 4m ).
Discussion
In the orthopaedic field, special attention is given to cartilage repair using tissue-engineering techniques Fig. 4 Histochemical analysis of paraffin sections of cartilage specimens. In the left top panels, images from samples taken at 12 and 20 weeks post-operatively stained with Safranin O. In the left bottom panels, Collagen II immunostainings from samples taken at 12 and 20 weeks post-operatively. a, g Untreated knee (sample F12left); b, h defect treated with cell-free PLGA scaffold (F14left); c, i defect treated with cellseeded PLGA scaffold (sample F6right); d, j untreated knee (sample F17left); e, k defect treated with cell-free PLGA scaffold (F16right); f, l defect treated with cell-seeded PLGA scaffold (sample F17right). m Graphical representation of the scores obtained at 12 and 20 weeks grouped together according to each treatment, where the average from each group is also graphically represented to highlight the similarity in their values. n Section from a knee treated with PLGA scaffolds loaded with chondrocytes (sample F16left) and stained for Sox9 (inset: zoomed view with arrows pointing to Sox9 positive cells). CS cell-seeded scaffold, S scaffold, L untreated lesion. Scale bar 600 lm due to the complexity of pathologies involving two types of distinct tissues: articular cartilage and subchondral bone. Accordingly, the use of either natural based polymers or synthetic materials in the manufacture of biocompatible scaffolds is currently a hot topic. Indeed, numerous studies have focused on the design of complex scaffolds, including the combination of two distinct layers or a gradient scaffold (reviewed by Rodrigues et al. 2011) . In the present study, PLGA was chosen because it is one of the few synthetic materials approved by the FDA as scaffolding material for clinical applications and it has been previously used in articular cartilage treatment, emerging as a valuable chondrocyte and MSC delivery vehicle (Sittinger et al. 1996; Uematsu et al. 2005) . Furthermore, the method followed for the manufacture of the scaffolds permitted to set a porosity level that allowed the ingrowth of host tissue as well as supporting the preloading with in vitro-expanded chondrocytes. Importantly, the scaffold structure allowed arthroscopic implantation making it an attractive material for clinical use and highlights the need for the use of large animal models in the development of new cartilage repair techniques; in particular, those species with size and physiology similar to humans. We used skeletally mature 2-year-old sheep (Kilborn et al. 2002) , and the osteochondral defects were modelled in weight bearing areas. For this purpose, the experimental defects were located in the central/ posterior region of the medial femoral condyle, with the aim of represent the clinical situation faced in humans. We chose to harvest cartilage cells from the shoulder, so both knees of each animal could be used in the study, in the same comparable conditions without additional lesions on the surrounding area that might influence the outcome of the treatments.
The use of chondrocytes allowed a significant improvement with respect to untreated controls at the macroscopic level, although this observation was not confirmed histologically, probably due to the short observation time. Therefore, it was not clear whether the addition of chondrocytes into the PLGA scaffolds could significantly accelerate the regeneration mechanisms.
To our knowledge, this is the first report of arthroscopic implantation of the PLGA scaffolds in the sheep knee. Published studies used arthrotomy procedures to implant the tissue engineered constructs (Córdoba et al. 2007; Erggelet et al. 2007; Niederauer et al. 2000) , because the difficulty of holding in place the implant without invasive procedures. The biomechanical characteristics of some of the constructs, as the ones made of chondrocytes and fibrin are too soft to hold in the defect site independently of the use of a periosteum patch. The need of development of this minimally invasive technique in the sheep knee has been mentioned by some authors (Munirah et al. 2007; Sha'ban et al. 2008 ) and the regulatory authorities require the use of the intended route of administration in humans and the intended delivery device in preclinical studies. This surgical technique has the recognized advantage of decreased morbidity associated with arthrotomy, more ethical experimental procedure and a final study that matches the clinical situation faced in human patients. On the other side there are two limitations that need to be acknowledged in the present study. Although the clinically accepted range of MRI covers from 0.2T to 3T (Ghazinoor et al. 2007) , the use of low-field MRI in this study made the detection of small cartilage abnormalities very challenging. The second point concerns to the sample size and the proximity of the two time endpoints for the euthanasia, which gave similar results, making possible to combine data for each treatment from both the 12-and 20-week groups for the statistical analysis. Future studies should evaluate the effects of a full regeneration process at later end-points (i.e., up to 12 months), other cell sources, and the appropriate therapeutic dose.
